We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Novartis Drops Patent Claims Against Ranbaxy

Law360 (September 21, 2007, 12:00 AM EDT) -- Pharmaceutical company Novartis International AG has indicated that it is dropping its patent claims against Ranbaxy Laboratories Limited over the top-selling hypertension drug Diovan.

In papers filed in the U.S. District Court for the District of New Jersey, Novartis said that it will dismiss its patent claims against Ranbaxy, because the generic drug maker had amended its abbreviated new drug application with the U.S. Food and Drug Administration, converting its paragraph IV certification to a paragraph III certification.

The effect of this conversion is that Ranbaxy...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.